benefits of glp-1 receptor agonists The cardiovascular effects beyond obesity and type 2 diabetes: An anti-atherosclerotic action The benefits of GLP-1 drugs

Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion

The prevalence of bullous pemphigoid was 0.0859% in total, with a trend toward a higher risk associated with vildagliptin use compared to the other DPP-4 inhibitors ( In total, however, the DPP-4 inhibitor class has demonstrated a good safety and tolerability spectrum that justifies the wide use of the class

24 Similarly, it is prudent to prescribe ursodeoxycholic acid during the first year of GLP-1 receptor agonist therapy to prevent gallstone formation

This extensive evaluation did not find a causal relationship between a therapy with incretin-based therapies and pancreatic safety

GLP-1 Receptor Agonists and the Hallmarks of Aging: A Systems-Level Analysis Aging is driven by interacting biological processes